Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO)
…, B Buecher, N Chapelle, O Dubreuil, N Fares… - Digestive and Liver …, 2018 - Elsevier
Introduction This document is a summary of the French Intergroup guidelines regarding the
management of gastric cancer published in October 2016, available on the website of the …
management of gastric cancer published in October 2016, available on the website of the …
Epidemiology, natural history, and risk factors of hepatocellular carcinoma
N Fares, JM Péron - La Revue du praticien, 2013 - europepmc.org
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver. It is
the sixth most common malignancy worldwide and the third cause of cancer-related mortality. …
the sixth most common malignancy worldwide and the third cause of cancer-related mortality. …
[HTML][HTML] An unusual phenotype occurs in 15% of mismatch repair-deficient tumors and is associated with non-colorectal cancers and genetic syndromes
M Jaffrelot, N Farés, AC Brunac, AP Laurenty… - Modern Pathology, 2022 - Elsevier
Immunohistochemistry (IHC) and/or MSI-PCR (microsatellite instability-polymerase chain
reaction) tests are performed routinely to detect mismatch repair deficiency (MMR-D). Classical …
reaction) tests are performed routinely to detect mismatch repair deficiency (MMR-D). Classical …
Incidence of venous thromboembolism in patients with newly diagnosed pancreatic cancer and factors associated with outcomes
…, M Deslandres, P Rivera, AP Laurenty, N Fares… - Gastroenterology, 2020 - Elsevier
Background & Aims Pancreatic ductal adenocarcinoma (PDAC) is associated with the highest
incidence of venous thromboembolism (VTE) of any cancer type. However, little is known …
incidence of venous thromboembolism (VTE) of any cancer type. However, little is known …
EpCAM-regulated intramembrane proteolysis induces a cancer stem cell-like gene signature in hepatitis B virus-infected hepatocytes
…, A Diab, PE Pascuzzi, L Lefrançois, N Fares… - Journal of …, 2016 - Elsevier
Background & Aims Hepatocytes in which the hepatitis B virus (HBV) is replicating exhibit
loss of the chromatin modifying polycomb repressive complex 2 (PRC2), resulting in re-…
loss of the chromatin modifying polycomb repressive complex 2 (PRC2), resulting in re-…
Special features of sarcomas developed in patients with Lynch syndrome: a systematic review.
…, C Christine, S Janick, G Rosine, F Nadim - Critical Reviews in …, 2023 - Elsevier
Lynch syndrome (LS) is a genetic predisposition leading to colorectal and non-colorectal
tumors such as endometrial, upper urinary tract, small intestine, ovarian, gastric, biliary duct …
tumors such as endometrial, upper urinary tract, small intestine, ovarian, gastric, biliary duct …
[HTML][HTML] Restoration of RNA helicase DDX5 suppresses hepatitis B virus (HBV) biosynthesis and Wnt signaling in HBV-related hepatocellular carcinoma
Rationale: RNA helicase DDX5 is downregulated during hepatitis B virus (HBV) replication,
and poor prognosis HBV-related hepatocellular carcinoma (HCC). The aim of this study is to …
and poor prognosis HBV-related hepatocellular carcinoma (HCC). The aim of this study is to …
Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis
M Bonnin, N Fares, B Testoni, Y Estornes, K Weber… - Journal of …, 2019 - Elsevier
Background & Aims Low levels of toll-like receptor 3 (TLR3) in patients with hepatocellular
carcinoma (HCC) are associated with poor prognosis, primarily owing to the loss of …
carcinoma (HCC) are associated with poor prognosis, primarily owing to the loss of …
DNA demethylation induces SALL4 gene re-expression in subgroups of hepatocellular carcinoma associated with Hepatitis B or C virus infection
Sal-like protein 4 (SALL4), an embryonic stem cell transcriptional regulator, is re-expressed
by an unknown mechanism in poor prognosis hepatocellular carcinoma (HCC), often …
by an unknown mechanism in poor prognosis hepatocellular carcinoma (HCC), often …
[HTML][HTML] CINSARC signature outperforms gold-standard TNM staging and consensus molecular subtypes for clinical outcome in stage II–III colorectal carcinoma
AC Brunac, J Fourquet, G Perot, M Jaffrelot… - Modern Pathology, 2022 - Elsevier
The outcome of stage II–III colorectal cancer (CRC) is highly variable and therapeutic choice
is currently based on TNM staging with a few additional biomarkers. However, studies show …
is currently based on TNM staging with a few additional biomarkers. However, studies show …